The State of the Art in Benign Hematology, Hemostasis, and Thrombosis: 2026 Update in Emerging Therapeutics symposium, hosted by Memorial Sloan Kettering Cancer Center (MSK), will take place in person on 16 October 2026, from 7:55 a.m. to 3:00 p.m., at the Zuckerman Research Center in New York City.

The one-day programme will review current and emerging approaches to venous thromboembolism, pulmonary embolism, myeloma-associated thrombosis, factor XI inhibitors, venous stenting, post-thrombotic syndrome, cancer therapy-related cytopenias, thrombopoietin receptor agonists, hemophagocytic lymphohistiocytosis, and immune thrombocytopenia.

Designed for hematologists, oncologists, advanced practice providers, trainees, nurses, and other healthcare professionals, the symposium will feature expert presentations, interactive discussion, and practical clinical cases. Early registration through 4 September 2026 ranges from $50 to $250, while general rates range from $100 to $525, depending on participant category.